Evaluating the Risk of Venous Thromboembolism in Transfeminine and Gender Diverse People: A Retrospective Analysis (Q29330)
Jump to navigation
Jump to search
No description defined
- Evaluating the Risk of Venous Thromboembolism in Transfeminine and Gender Diverse People: A Retrospective Analysis.
- Evaluating the Risk of Venous Thromboembolism in Transfeminine and Gender Diverse People
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Evaluating the Risk of Venous Thromboembolism in Transfeminine and Gender Diverse People: A Retrospective Analysis |
No description defined |
|
Statements
The risk of venous thromboembolism (VTE) with feminizing gender-affirming hormone therapy is an area of concern. (English)
OBJECTIVE (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
This analysis aimed to assess whether gender-affirming hormone therapy and other potential risk factors are associated with VTE in transfeminine and gender diverse individuals. (English)
OBJECTIVE (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
We conducted a chart review of 2126 transfeminine and gender diverse adults receiving care within a large urban health system. (English)
METHODS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
The primary outcomes were the prevalence of VTE and odds ratios for the association of VTE with insurer, use of estrogen, and select comorbidities. (English)
METHODS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
A history of VTE was documented in 0.8% of the cohort. (English)
RESULTS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
Those with a history of VTE were older (P < .001), more often self-identified as Hispanic or Black compared to White or Asian (P < .05) and were more likely to have Medicaid or Medicare (P < .01) when compared to those without a history of VTE. (English)
RESULTS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
The prevalence of hyperlipidemia (P < .001), diabetes mellitus (P < .05), and hypercoagulable conditions (P < .001) were all greater in the positive VTE group. (English)
RESULTS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
Hyperlipidemia (P < .001), diabetes mellitus (P < .05), and insurer (P < .05) were associated with increased odds of VTE in univariate analyses. (English)
RESULTS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
None of the exposure variables analyzed were associated with VTE when controlling for age, race, and the number of comorbidities. (English)
RESULTS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
The prevalence of VTE in our cohort was lower than previously observed. (English)
CONCLUSIONS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
VTE was not associated with any one risk factor, including estrogen use, when controlling for age, race, and the number of comorbidities. (English)
CONCLUSIONS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
Those of advanced age and those with multiple cardiometabolic comorbidities may benefit from increased surveillance and mitigation of modifiable risk factors. (English)
CONCLUSIONS (English)
Copyright © 2024 AACE. Published by Elsevier Inc. All rights reserved. (English)
2024
Daniel J (English)
Slack (English)
DJ
Nithya (English)
Krishnamurthy (English)
N
Derek (English)
Chen (English)
D
Felix G (English)
Contreras-Castro (English)
FG
Joshua D (English)
Safer (English)
JD
3 November 2024
3 November 2024
Disclosure The authors have no conflicts of interest to disclose. (English)